SEC Form 4 · accession 0001971798-26-000005
NEUROONE MEDICAL TECHNOLOGIES Corp · NMTC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David J. Wambeke
Officer — Chief Business Officer
Period of report
Aug 27, 2026
Accepted (ET)
Sep 8, 2026 · 8:31 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001500198
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 27, 2026 | P | 33,333 | $2.01 | A | 199,999 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF2 | $1.77 | Aug 28, 2026 | A | 35,000 | A | — | Aug 27, 2036 | Common Stock | 35,000 | 35,000 | D |
Explanation of responses
- F1The price represents the weighted average price of the multiple transactions reported on this line. The shares were sold at prices ranging from $2.00 and $2.017 per share. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price.
- F225% will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments.